The AFPPS, ukCAP, and APACC trials reported incident colorectal
cancer. CALGB 9270 was not included in this analysis because it
studied a population with a history of colorectal cancer, whereas the
remaining trials involved participants with no history of colorectal
cancer. As would be expected in any population that was under
endoscopic surveillance, the numbers of colorectal cancers observed
were small. Across the combined AFPPS, ukCAP, and APACC
study populations, the percentage of participants diagnosed with
incident colorectal cancer was similar in the any-dose aspirin and
placebo groups (0.54% vs 0.62%, respectively; P = .81).